The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

In conclusion, data from high-quality RCTs for ranibizumab and dexamethasone IVT have demonstrated that both new agents have promising outcomes for the treatment of BRVO and CRVO, and constitute ...

“[By] using these techniques, I now offer a holistic and comprehensive treatment that promises not just relaxation, but transformative rejuvenation” — which is, exactly where the cultural ...

As previously reported in the treatment of high-altitude pulmonary edema, 6 the effective diuresis with furosemide and morphine was greater than that with furosemide alone. Nineteen out of 24 ...

[6] However, differences in the improvement in VA between the two treatment groups became apparent only after 12 months, and 12% of patients treated with laser therapy experienced decreases in VA ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

A pioneering new treatment promises to tackle a wider range of cancers, with fewer side-effects than conventional radiotherapy. It also takes less than a second. In a series of vast underground ...

OCU200 is a recombinant fusion protein targeting integrin receptors with anti-inflammatory and anti-VEGF properties, potentially transforming DME treatment ... phase 1 clinical trial for diabetic ...